In-House vs Outsourced Pet Food Production

At some point most growing brands ask whether to build their own production or continue using a contract manufacturer. It is framed as a cost question and it is really a question about capital, control and how fast the brand needs to move.

What each model is good at

The two columns are not a ranking; they describe different risk profiles. Own production converts fixed cost into lower variable cost, which rewards volume and punishes under-utilisation. Contract manufacturing keeps costs variable, which rewards flexibility and punishes nothing except the margin per unit.

The question that usually decides it

Most of the decision comes down to whether the brand can predict its volume with enough confidence to fill a line. A plant that runs below capacity still carries its costs, and the contribution margin advantage evaporates — or inverts — far sooner than most business cases assume.

Three secondary factors also carry weight. The first is process secrecy: where the formulation or process is a genuine competitive asset, keeping it in-house has value that is difficult to price but real. The second is whether the brand needs capability it does not have — a format, a technology, a certification — which may be quicker to buy through a partner than to build. The third is management attention: running a plant is an operating business in its own right, and a brand founder's time diverted to production is time not spent on the market.

The hybrid that most brands end up with

In practice the answer is frequently both. A brand runs its own production for the core range where volume is predictable and the process is strategic, and uses contract manufacturers for extensions, seasonal products, formats it does not run, or a launch it wants to test before committing equipment.

This structure requires the outsourcing relationships to be set up properly, because they carry the IP and continuity issues described elsewhere on this site. Two clauses matter particularly in a hybrid model: who owns the formula for products made outside, and what right the brand has to move a product between its own plant and a partner without renegotiating. We cover the first in who owns the formula, and the general terms in our OEM agreement checklist.

A staged approach that limits the risk

Because the decision is largely about volume confidence, it does not have to be made in a single step. A sequence that limits exposure looks like this:

1. Launch through a contract manufacturer to establish real demand rather than forecast demand.
2. Watch the capacity utilisation figure — the point at which a partner's cost per unit becomes the constraint on growth, not the market.
3. Bring one format in-house first, ideally the highest-volume, least complex product in the range, so the learning curve is contained.
4. Keep the partner relationship active for extensions and peaks rather than exiting it, since capacity you no longer hold is capacity you cannot call on.

The value of the sequence is that each step is funded by evidence from the previous one. The value of keeping the partner is that a plant is sized for the peak it was built for, and demand does not always arrive on schedule.

Questions buyers ask us

Is contract manufacturing more expensive?

Per unit, usually yes; it also requires no capital and scales down with demand. The comparison only becomes meaningful once a realistic volume forecast is applied to both options.

What do brands most often underestimate about building a plant?

The time required — for premises, equipment, people and the documentation that markets require — and the fixed cost carried during any period of low demand.

What should we ask a contract manufacturer before relying on them?

Which formats run on their own lines, capacity available to us, MOQ, lead time, documentation they can issue, and who owns the formula.